BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab
A clinical trial is underway to evaluate Navlimetostat combined with pembrolizumab and chemotherapy in NSCLC patients with MTAP deletion.
Asset / Drug
Drug and asset intelligence for Navlimetostat with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.